Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionation Radiotherapy + Sintilimab + GM-CSF + Fruquintinib in MSS mCRC
NCT05292417Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, fruquintinib and sargramostim in colorectal cancer (CRC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Progression-free survival at 2 years. Status: unknown.
02
Drugs
sintilimabfruquintinibsargramostim
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05292417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292417.